Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Share-based Compensation (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Share-based Compensation for 14 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 5.05% year-over-year to $2.2 million, compared with a TTM value of $10.3 million through Dec 2025, down 20.24%, and an annual FY2025 reading of $10.3 million, down 20.24% over the prior year.
  • Share-based Compensation was $2.2 million for Q4 2025 at Heron Therapeutics, down from $2.9 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $13.9 million in Q2 2023 and bottomed at $2.2 million in Q4 2025.
  • Average Share-based Compensation over 5 years is $7.3 million, with a median of $7.3 million recorded in 2023.
  • The sharpest move saw Share-based Compensation skyrocketed 34.26% in 2023, then tumbled 67.12% in 2024.
  • Year by year, Share-based Compensation stood at $12.9 million in 2021, then decreased by 18.42% to $10.5 million in 2022, then tumbled by 58.87% to $4.3 million in 2023, then plummeted by 46.92% to $2.3 million in 2024, then dropped by 5.05% to $2.2 million in 2025.
  • Business Quant data shows Share-based Compensation for HRTX at $2.2 million in Q4 2025, $2.9 million in Q3 2025, and $2.8 million in Q2 2025.